Related Experiment Videos
[Urinary incontinence: anticholinergic treatment].
1Servicio de Urología, Hospital Clinico San Carlos, Madrid. mjcidre00@hotmail.com
Revista De Medicina De La Universidad De Navarra
|April 7, 2005
Summary
Anticholinergic drugs, targeting muscarinic receptors, are a primary treatment for overactive bladder. This review covers current options like oxybutynin and tolterodine, and emerging therapies such as botulinum toxin.
Area of Science:
- Urology
- Pharmacology
- Neuroscience
Context:
- The bladder and urethra function as a unit regulated by the nervous system.
- Detrusor muscle contraction relies on acetylcholine stimulating muscarinic receptors.
- Anticholinergic drugs target these receptors, forming a cornerstone of overactive bladder treatment.
Purpose:
- To provide an updated review of current anticholinergic treatments for overactive bladder.
- To discuss recent developments and the status of various therapeutic agents.
- To highlight emerging treatments like botulinum toxin injections.
Summary:
- Anticholinergic drugs are effective first-line treatments for overactive bladder, improving bladder capacity and reducing detrusor muscle activity.
- The review examines available and upcoming medications such as oxybutynin, tolterodine, and trospium chloride.
- It also addresses newer options including uroselective agents (darifenacin, solifenacin), propoverine, and botulinum toxin for refractory cases.
Impact:
- Offers a comprehensive overview of pharmacological interventions for overactive bladder.
- Informs clinicians about the current landscape and future directions in bladder hyperactivity management.
- Supports evidence-based treatment decisions for patients with overactive bladder.